Saint Luke's Health System   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Kansas City MO United States (1882)

Organization Overview

First Clinical Trial
2004
NCT00081731
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Mid America Heart Institute, Saint Luke's Hospital | Mid-America Heart Institute, St. Luke's Hospital, Kansas City, MO | Saint Luke's Cancer Institute | Saint Luke's Cancer Institute(SLCI) | Saint Luke's Cardiovascular Consultants | Saint Luke's Health System | Saint Luke's Health System Foundation | Saint Luke's Hospital of Kansas City | Saint Luke's Mid America Heart Institute | Sanjaya Gupta | St. Luke's Health System

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Atherosclerosis (Phase 3)

Breast Neoplasms (Phase 2)

Cardiomyopathies (Phase 2)

Cardiomyopathy, Dilated (Phase 2)

Cardiovascular Diseases (Phase 3)

Clostridium Infections (Phase 2)

Coronary Artery Disease (Phase 4)

Heart Failure (Phase 4)

Hyperglycemia (Phase 4)

Hypertension, Renovascular (Phase 3)

Infarction (Phase 4)

Lupus Erythematosus, Systemic (Phase 2)

Myocardial Infarction (Phase 4)

Renal Artery Obstruction (Phase 3)

Respiratory Insufficiency (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial APIs: 13